Ken Griffin Arrowhead Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $174,240 - $265,860	-9,000 Reduced 19.44%	37,300 $722,000
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $559,872 - $722,944	25,600 Added 123.67%	46,300 $1.2 Million
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $1.55 Million - $2.25 Million	-56,900 Reduced 73.32%	20,700 $592,000
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $254,400 - $372,360	12,000 Added 18.29%	77,600 $2.37 Million
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $497,800 - $685,520	19,000 Added 40.77%	65,600 $1.76 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $407,592 - $670,356	-16,200 Reduced 25.8%	46,600 $1.66 Million
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $1.11 Million - $1.81 Million	-47,000 Reduced 42.81%	62,800 $1.6 Million
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $1.1 Million - $1.6 Million	-39,400 Reduced 26.41%	109,800 $4.45 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $811,862 - $1.32 Million	27,400 Added 22.5%	149,200 $4.93 Million

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.